Brief: Diffusion Pharmaceuticals To Initiate Phase 2 Trial In Patients With Glioblastoma Multiforme Incorporating Innovative Imaging Methodology To Evaluate Tumor Oxygenation

CervoMed

26/07/2022 12:51

July 26 (Reuters) - Diffusion Pharmaceuticals Inc  DFFN.O :
    * DIFFUSION PHARMACEUTICALS TO INITIATE PHASE 2 TRIAL IN
PATIENTS
WITH GLIOBLASTOMA MULTIFORME INCORPORATING INNOVATIVE IMAGING
METHODOLOGY TO EVALUATE TUMOR OXYGENATION
    * DIFFUSION PHARMACEUTICALS  - ALIGNS WITH FDA ON DESIGN OF
PHASE
2 SAFETY & EFFICACY STUDY OF TSC IN NEWLY DIAGNOSED GBM PATIENTS
    * DIFFUSION PHARMACEUTICALS INC - EXPECTS TO INITIATE TRIAL
BY END
OF 2022 AND ANTICIPATES DOSING FIRST PATIENT IN TRIAL IN Q1 OF
2023

Source text for Eikon:  ID:nGNX2T86dP 
Further company coverage:  DFFN.O 

 ((Reuters.Briefs@thomsonreuters.com;))